Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COLUMN
COLUMN
- Maurer’s Healthcare Insight (141)
January 30, 2012
- Maurer’s Healthcare Insight (140)
December 26, 2011
- Maurer’s Healthcare Insight (139)
December 12, 2011
- Maurer’s Healthcare Insight (138)
November 21, 2011
- Maurer’s Healthcare Insight（137）
October 17, 2011
- Maurer’s Healthcare Insight (136)
September 12, 2011
- Maurer's Healthcare Insight (135)
August 15, 2011
- Maurer's Healthcare Insight (134)
August 1, 2011
- Maurer's Healthcare Insight (133)
July 11, 2011
- Maurer's Healthcare Insight (132)
May 30, 2011
- Maurer's Healthcare Insight (131)
April 18, 2011
- Maurer's Healthcare Insight (130)
January 24, 2011
- Maurer's Healthcare Insight (129)
January 3, 2011
- Maurer's Healthcare Insight (128)
December 13, 2010
- Maurer's Healthcare Insight (127)
November 29, 2010
- Maurer's Healthcare Insight (126)
November 8, 2010
- Maurer's Healthcare Insight (125)
October 25, 2010
- Maurer's Healthcare Insight (124)
October 11, 2010
- Maurer's Healthcare Insight (123)
July 12, 2010
- Maurer's Healthcare Insight (122)
May 31, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…